Erlotinib Active Not Recruiting Phase 2 Trials for Epidermal Growth Factor Receptor / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01897480A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
NCT00553800Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
NCT00977470Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
NCT02770014Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
NCT01573702Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
NCT00137800Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients